Related Experiment Video

Updated: Oct 4, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Intercellular adhesive molecule 1(ICAM-1) and acute ischaemic stroke: Role of statins

Hayder Fadhel Al-Rubiay1, Hayder Mutter Al-Kuraishy2, Ali Ismail Al-Gareeb2

  • 1Department of Medicine, College of Medicine, University of Al-Mustansiriya, University, Baghdad, Iraq.

JPMA. the Journal of the Pakistan Medical Association
|February 7, 2022
PubMed

Insights

Atorvastatin and rosuvastatin effectively lower Intercellular adhesive molecule 1 (ICAM-1) levels in acute ischemic stroke (AIS) patients. Both statins show promise in managing AIS, with atorvastatin demonstrating a slightly greater reduction in ICAM-1 and stroke risk score.

Area of Science:

  • Cardiology and Neurology
  • Pharmacology
  • Biomarkers

Background:

  • Acute ischemic stroke (AIS) is a significant health concern.
  • Intercellular adhesive molecule 1 (ICAM-1) is implicated in the pathophysiology of AIS.
  • Understanding the impact of statin therapy on ICAM-1 is crucial for managing AIS.

Purpose of the Study:

  • To investigate the differential effects of atorvastatin and rosuvastatin on ICAM-1 levels in AIS patients.
  • To evaluate ICAM-1 as a biomarker in AIS.
  • To compare the efficacy of atorvastatin and rosuvastatin in reducing ICAM-1.

Main Methods:

  • A case-control study involving 66 AIS patients and 22 healthy controls.
  • Patients were divided into four groups: AIS on atorvastatin, AIS on rosuvastatin, AIS not on statins, and healthy controls.
  • Serum ICAM-1 levels, anthropometric, lipid, and pressure profiles were assessed.

Main Results:

  • AIS patients exhibited higher ICAM-1 levels compared to controls.
  • Statin therapy significantly reduced ICAM-1 levels in AIS patients.
  • Atorvastatin showed a trend towards greater ICAM-1 reduction and a significantly lower stroke risk score compared to rosuvastatin.

Conclusions:

  • ICAM-1 serves as a surrogate biomarker for AIS, particularly in patients with poor cardio-metabolic profiles.
  • Both atorvastatin and rosuvastatin are effective in attenuating AIS by lowering ICAM-1 serum levels.
  • Atorvastatin may offer a slight advantage over rosuvastatin in managing AIS based on ICAM-1 levels and stroke risk score.
Abstract

Keywords:
Acute ischemic stroke, Atorvastatin, Rosuvastatin, Intercellular adhesive molecule 1.

More Related Videos

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.1K
Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain12:14

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain

Published on: February 12, 2016

35.3K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
930
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
58
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.5K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.7K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
44